The norepinephrine transporter (NET) radioligand (S,S)-[18F]FMeNER-D2 shows significant decreases in NET density in the human brain in Alzheimer's disease: A post-mortem autoradiographic study

Neurochemistry International

Volumn 56, Issue 6-7, 2010, Pages 789-798

  Gulyás, Balázs ^a   Brockschnieder, Damian ^b   Nag, Sangram ^a   Pavlova, Elena ^a   Kása, Péter ^c   Beliczai, Zsuzsa ^d   Légrádi, Ádám ^d   Gulya, Károly ^d   Thiele, Andrea ^b   Dyrks, Thomas ^b   Halldin, Christer ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY OF SZEGED   (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

(S,S) 18F FMeNER D2; Alzheimer's disease (AD); Human brain; Immunohistochemistry; LC; Norepinephrine transporter (NET); Positron emission tomography (PET); Receptor binding; Thalamus; Whole hemisphere autoradiography

Indexed keywords

NORADRENALIN TRANSPORTER; RADIOLIGAND; REBOXETINE F 18; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BRAIN SIZE; CONTROLLED STUDY; DENSITY; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LOCUS CERULEUS; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; THALAMUS;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AUTORADIOGRAPHY; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; FLUORINE RADIOISOTOPES; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; LOCUS COERULEUS; MIDDLE AGED; MORPHOLINES; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; THALAMUS;

EID: 77952292091     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.03.001     Document Type: Article

References (61)

1. Andreasen N., Zetterberg H. Amyloid-related biomarkers for Alzheimer's disease. Curr. Med. Chem. 2008, 15:766-771.
2. Andrews T.J., Halpern S.D., Purves D. Correlated size variations in human visual cortex, lateral geniculate nucleus, and optic tract. J. Neurosci. 1997, 17:2859-2868.
3. 18F-FMeNER-D2. J. Nucl. Med. 2008, 49:1270-1276.
4. Banati R.B. Visualising microglial activation in vivo. Glia 2002, 40:206-217.
5. Cai L., Innis R.B., Pike V.W. Radioligand development for PET imaging of beta-amyloid (Abeta)-current status. Curr. Med. Chem. 2007, 14:19-52.
6. Chen M.K., Guilarte T.R. Translocator protein 18kDa (TSPO) molecular sensor of brain injury and repair. Pharmacol. Ther. 2008, 118:1-17.
7. Dollé F., Luus C., Reynolds A., Kassiou M. Radiolabelled molecules for imaging the translocator protein (18kDa) using positron emission tomography. Curr. Med. Chem. 2009, 16:2899-2923.
8. 2 for MAO B mapping. J. Nucl. Med. 1995, 36:1255-1262.
9. Fuller S., Münch G., Steele M. Activated astrocytes: a therapeutic target in Alzheimer's disease?. Expert Rev. Neurother. 2009, 9:1585-1594.
10. Gavish M., Bachman I., Shoukrun R., Katz Y., Veenman L., Weisinger G., Weizman A. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev. 1999, 51:629-650.
11. German D.C., Walker B.S., Manaye K., Smith W.K., Woodward D.J., North A.J. The human locus coeruleus: computer reconstruction of cellular distribution. J. Neurosci. 1988, 8:1776-1788.
12. Ghose S., Fujita M., Morrison P., Uhl G., Murphy D.L., Mozley P.D., Schou M., Halldin C., Innis R. Specific in vitro binding of (S,S)-[3H]MeNER to norepinephrine transporters. Synapse 2005, 56:100-104.
13. Gulyás B., Makkai B., Kása P., Gulya K., Bakota L., Várszegi S., Beliczai Z., Andersson J., Csiba L., Thiele A., Dyrks T., Suhara T., Suzuki K., Higuchi M., Halldin C. A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochem. Int. 2009, 54:28-36.
14. Haglund M., Sjöbeck M., Englund E. Locus ceruleus degeneration is ubiquitous in Alzheimer's disease: possible implications for diagnosis and treatment. Neuropathology 2006, 26:528-532.
15. Hall H., Halldin C., Farde L., Sedvall G. Whole hemisphere autoradiography of the postmortem human brain. Nucl. Med. Biol. 1998, 25:715-719.
16. Hampel H., Bürger K., Teipel S.J., Bokde A.L., Zetterberg H., Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008, 4:38-48.
17. Heneka M.T., Galea E., Gavriluyk V., Dumitrescu-Ozimek L., Daeschner J., O'Banion M.K., Weinberg G., Klockgether T., Feinstein D.L. Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 2002, 22:2434-2442.
18. Heneka M.T., Ramanathan M., Jacobs A.H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., Sastre M., Galldiks N., Zimmer A., Hoehn M., Heiss W.D., Klockgether T., Staufenbiel M. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 2006, 26:1343-1354.
19. Hoogendijk W.J., Feenstra M.G., Botterblom M.H., Gilhuis J., Sommer I.E., Kamphorst W., Eikelenboom P., Swaab D.F. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann. Neurol. 1999, 45:82-91.
20. Johansson A., Engler H., Blomquist G., Scott B., Wall A., Aquilonius S.M., Långström B., Askmark H. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. Neurol. Sci. 2007, 255(1/2):17-22.
21. Johnström P., Davenport A.P. Imaging and characterization of radioligands for positron emission tomography using quantitative phosphor imaging autoradiography. Receptor Binding Techniques 2005, 203-216. Humana Press, New Jersey. A.P. Davenport (Ed.).
22. Kalinin S., Gavrilyuk V., Polak P.E., Vasser R., Zhao J., Heneka M.T., Feinstein D.L. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging 2007, 28:1206-1214.
23. Kassiou M., Meikle S.R., Banati R.B. Ligands for peripheral benzodiazepine binding sites in glial cells. Brain Res. Brain Res. Rev. 2005, 48:207-210.
24. Klimek V., Stockmeier C., Overholser J., Meltzer H.Y., Kalka S., Dilley G., Ordway G.A. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J. Neurosci. 1997, 17:8451-8458.
25. Kelényi G. Thioflavin S fluorescent and Congo red anisotropic staining in the histologic demonstration of amyloid. Acta Neuropathol. 1967, 7:336-348.
26. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
27. Kortvely E., Varszegi S., Palfi A., Gulya K. Intracellular targeting of calmodulin mRNAs in primary hippocampal cells. J. Histochem. Cytochem. 2003, 51:541-544.
28. Kumlien E., Bergström M., Lilja A., Andersson J., Szekeres V., Westerberg C.E., Westerberg G., Antoni G., Långström B. Positron emission tomography with [11C]deuterium-deprenyl in temporal lobe epilepsy. Epilepsia 1995, 36:712-721.
29. Lyness S.A., Zarow C., Chui H.C. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol. Aging 2003, 24:1-23.
30. Matthews K.L., Chen C.P., Esiri M.M., Keene J., Minger S.L., Francis P.T. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol. Psychiatry 2002, 51:407-416.
31. Nordberg A. Amyloid imaging in Alzheimer's disease. Curr. Opin. Neurol. 2007, 20:398-402.
32. Nordberg A. Amyloid imaging in Alzheimer's disease. Neuropsychologia 2008, 46:1636-1641.
33. Ordway G.A., Stockmeier C.A., Cason G.W., Klimek V. Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. J. Neurosci. 1997, 17:1710-1719.
34. Razifar P., Axelsson J., Schneider H., Langström B., Bengtsson E., Bergström M. A new application of pre-normalized principal component analysis for improvement of image quality and clinical diagnosis in human brain PET studies-clinical brain studies using [11C]-GR205171, [11C]-l-deuterium-deprenyl, [11C]-5-hydroxy-l-tryptophan, [11C]-l-DOPA and Pittsburgh vompound-B. Neuroimage 2006, 33:588-598.
35. Reutens D.C. Imaging monoamine oxidase B receptor mapping. Adv. Neurol. 2000, 83:173-176.
36. Rodríguez J.J., Olabarria M., Chvatal A., Verkhratsky A. Astroglia in dementia and Alzheimer's disease. Cell Death Differ. 2009, 16:378-385.
37. Sanders J.D., Happe H.K., Bylund D.B., Murrin L.C. Development of the norepinephrine transporter in the rat CNS. Neuroscience 2005, 130:107-117.
38. Schou M., Halldin C., Sóvágó J., Pike V.W., Hall H., Gulyás B., Mozley P.D., Dobson D., Shchukin E., Innis R.B., Farde L. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 2004, 53:57-67.
39. Schou M., Halldin C., Pike V.W., Mozley P.D., Dobson D., Innis R.B., Farde L., Hall H. Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2. Eur. Neuropsychopharmacol. 2005, 15:517-520.
40. Schroeter S., Apparsundaram S., Wiley R.G., Miner L.H., Sesack S.R., Blakely R.D. Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter. J. Comp. Neurol. 2000, 420:211-232.
41. Schwab C., McGeer P.L. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J. Alzheimers Dis. 2008, 13:359-369.
42. Seneca N., Gulyás B., Varrone A., Schou M., Airaksinen A., Tauscher J., Vandenhende F., Kielbasa W., Farde L., Innis R.B., Halldin C. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2. Psychopharmacology (Berl) 2006, 188:119-127.
43. Smith H.R., Beveridge T.J., Porrino L.J. Distribution of norepinephrine transporters in the non-human primate brain. Neuroscience 2006, 138:703-714.
44. Svedberg M.M., Hall H., Hellström-Lindahl E., Estrada S., Guan Z., Nordberg A., Långström B. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem. Int. 2009, 54:347-357.
45. Szot P., Leverenz J.B., Peskind E.R., Kiyasu E., Rohde K., Miller M.A., Raskind M.A. Tyrosine hydroxylase and norepinephrine transporter mRNA expression in the locus coeruleus in Alzheimer's disease. Brain Res. Mol. Brain Res. 2000, 84:135-140.
46. Szot P., White S.S., Greenup J.L., Leverenz J.B., Peskind E.R., Raskind M.A. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J. Neurosci. 2006, 26:467-478.
47. Takano A., Gulyás B., Varrone A., Karlsson P., Schou M., Airaksinen A.J., Vandenhende F., Tauscher J., Halldin C. Imaging the norepinephrine transporter with positron emission tomography: initial human studies with (S,S)-[(18)F]FMeNER-D(2). Eur. J. Nucl. Med. Mol. Imaging 2008, 35:153-157.
48. Takano A., Halldin C., Varrone A., Karlsson P., Sjöholm N., Stubbs J.B., Schou M., Airaksinen A.J., Tauscher J., Gulyás B. Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[(18)F]FMeNER-D(2) a human whole-body PET study. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:630-636.
49. Takano A., Varrone A., Gulyás B., Karlsson P., Tauscher J., Halldin C. Mapping of the norepinephrine transporter in the human brain using PET with (S,S)-[18F]FMeNER-D2. Neuroimage 2008, 42:474-482.
50. Takano A., Gulyás B., Varrone A., Halldin C. Comparative evaluations of norepinephrine transporter radioligands with reference tissue models in rhesus monkeys: (S,S)-[18F]FMeNER-D2 and (S,S)-[11C]MeNER. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:1885-1891.
51. Takano A., Gulyás B., Varrone A., Maguire R.P., Halldin C. Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2). Eur. J. Nucl. Med. Mol. Imaging 2009, 36:1308-1314.
52. Tejani-Butt S.M., Yang J., Zaffar H. Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease. Brain Res. 1993, 631:147-150.
53. Tellioglu T., Robertson D. Genetic or acquired deficits in the norepinephrine transporter: current understanding of clinical implications. Expert Rev. Mol. Med. 2001, 19:1-10.
54. Thal D.R., Braak H. Post-mortem diagnosis of Alzheimer's disease. Pathologe 2005, 26:201-213.
55. Tuohy E., Leahy C., Dockery P., Fraher J., Fitzgerald E., Galvin R., Dansie P. An anatomical and MRI study of the human thalamus. J. Anat. 2004, 204:527-528.
56. Varnäs K. Distribution of Serotonin Receptors and Transporters in the Human brain: Implications for Psychosis. PhD Thesis 2005, Karolinska Institute.
57. Varnäs K., Halldin C., Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum. Brain Mapp. 2004, 22:246-260.
58. Venneti S., Lopresti B.J., Wiley C.A. The peripheral benzodiazepine receptor (translocator protein 18kDa) in microglia: from pathology to imaging. Prog. Neurobiol. 2006, 80:308-322.
59. Vizi E.S. Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol. Rev. 2000, 52:63-89.
60. Wilson A.A., Johnson D.P., Mozley D., Hussey D., Ginovart N., Nobrega J., Garcia A., Meyer J., Houle S. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl. Med. Biol. 2003, 30:85-92.
61. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 2003, 60:337-341.